In non-breast cancer settings, a high level of the c-myc protein is reported as a predictive biomarker for ClpP agonists in glioblastoma [316], and mutation of succinate dehydrogenase is proposed as a potential biomarker in neuroendocrine tumors [317]. Here, CLPP is linked to glioblastoma.